Document is current
Any future updates will be listed below
-
Authors
Lu, Linbin https://orcid.org/0000-0003-3779-3457
Zheng, Peichan https://orcid.org/0000-0003-3149-9978
Pan, Yan https://orcid.org/0009-0006-3445-8265
Huang, Shanshan https://orcid.org/0000-0001-6706-5894
Shao, Erqian https://orcid.org/0009-0008-4892-0195
Huang, Yan
Wang, Xuewen
Chen, Yayin https://orcid.org/0000-0001-9690-5063
Cuo, Gongbao
Yang, Hongyi
Guo, Wangting https://orcid.org/0009-0009-3363-6033
Shi, Yanhong
Wu, Zhixian https://orcid.org/0000-0002-0708-6770
Chen, Xiong https://orcid.org/0000-0001-5316-6512
- License Information
-
More Information
Article History
Received: 2 January 2023
Revised: 11 May 2023
Accepted: 19 June 2023
First Online: 8 July 2023
Competing interests
: The authors declare no competing interests.
: This is a secondary analysis based on IMbrave 150 study (ClinicalTrials.gov number, NCT03434379), and the Data Use Agreement with Research Plan is proved by the vivli platform ().
